Mallinckrodt Names Leslie Donato to Board of Directors

Rhea-AI Summary

Mallinckrodt (NYSE:MNK) has appointed Leslie Donato to its Board of Directors, completing its nine-member board following the recent merger with Endo, Inc. As former Executive Vice President and Chief Strategy Officer of Cencora, Donato brings over 30 years of healthcare industry experience and a track record of executing successful M&A strategies, having deployed over $10 billion in capital at Cencora and contributing to a 130% market cap increase over five years.

The appointment follows Mallinckrodt's August 1, 2025 merger with Endo, creating a global therapeutics leader. The board now comprises four members from each legacy company, with Donato jointly selected as the ninth member. Her extensive experience includes leadership roles at Bayer Healthcare Pharmaceuticals and McKinsey & Company.

Positive

• Strategic appointment brings extensive healthcare industry expertise with over 30 years of experience
• Completion of board structure following major Endo merger positions company for integrated governance
• New director's track record includes executing $10B+ in M&A deals and achieving 130% market cap growth at Cencora

Negative

• None.

Appointment of Former Cencora Executive Completes Nine-Member Board

DUBLIN, Aug. 4, 2025 /PRNewswire/ -- Mallinckrodt plc today announced that Leslie Donato has been appointed to the Company's Board of Directors, bringing the board's composition to a total of nine members.

An accomplished healthcare industry executive with broad expertise across strategy, corporate development, marketing, commercialization, and product development, Ms. Donato most recently served as Executive Vice President and Chief Strategy Officer of Cencora, Inc., a leading global pharmaceutical solutions organization. While at Cencora, she executed an ambitious M&A and growth strategy, committing over $10 billion in capital and contributing to a 130% increase in Cencora's market capitalization over five years.

Her appointment follows Mallinckrodt's announcement on August 1, 2025, that it had completed its merger with Endo, Inc., to create a global, scaled, diversified therapeutics leader. The company's board now consists of four members from each of the legacy companies, and Ms. Donato, who was jointly selected by her fellow board members.

"We are delighted to welcome Leslie to Mallinckrodt's Board of Directors," said Board Chair Paul Efron. "Her wealth of experience in the healthcare industry will inform the board's strategic discussions and provide valuable insight for setting the direction of the company. We look forward to the contribution that we know Leslie will make to the board's decision-making at Mallinckrodt."

Ms. Donato's career in healthcare spans more than 30 years. Prior to Cencora, which she joined in 2019, Ms. Donato spent 10 years at Bayer Healthcare Pharmaceuticals, where she led a number of businesses before becoming the head of strategy. Prior to Bayer, Ms. Donato was a partner at McKinsey & Company, where she spent 14 years helping executives improve performance as the leader of the firm's Pharmaceutical & Medical Products Marketing & Sales Practice and a founding partner of its Philadelphia office.

"I am privileged to have the opportunity to help shape Mallinckrodt's new future," said Ms. Donato. "The teams from Mallinckrodt and Endo, who are now joined under one company, are poised for greater success, and I could not be more excited to join the board at a pivotal moment in the company's history."

Ms. Donato also serves on the board of Virtua Health System, a leading academic nonprofit healthcare system in southern New Jersey, and COPILOT, a Florida-based leader in transforming patient access and support solutions for the life sciences industry. She holds a Bachelor of Arts in Economics and Public Policy from Swarthmore College and an MBA in Finance and Healthcare Management from The Wharton School. 

About Mallinckrodt

Mallinckrodt is a leading provider of life-enhancing therapeutics focused on addressing unmet patient needs and a world-class manufacturer of high-quality generics, sterile injectables, and active pharmaceutical ingredients.

Our company consists of multiple wholly owned subsidiaries that operate in two businesses. Our Brands business is focused on autoimmune and rare diseases in areas including endocrinology, gastroenterology, hepatology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology, and urology. Our Par Health business includes generic drugs, sterile injectables, and active pharmaceutical ingredients. To learn more, visit www.MNK-Endo.com.

Contacts

Investors
Bryan Reasons
Executive Vice President and Chief Financial Officer
bryan.reasons@mnk.com 

Media
Michael Freitag / Aura Reinhard / Catherine Simon
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449

Mallinckrodt, the "M" brand mark, the Mallinckrodt Pharmaceuticals logo, Endo and the Endo logo are trademarks owned or licensed by a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2025.

View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-names-leslie-donato-to-board-of-directors-302519822.html

SOURCE Mallinckrodt plc

FAQ

Who is Leslie Donato and what is her role at Mallinckrodt (MNK)?

Leslie Donato is the newly appointed Board Director at Mallinckrodt, completing its nine-member board. She previously served as Executive Vice President and Chief Strategy Officer at Cencora, with over 30 years of healthcare industry experience.

How many members are on Mallinckrodt's board after Leslie Donato's appointment?

Mallinckrodt's board now has nine members, with four members from each legacy company (Mallinckrodt and Endo) and Leslie Donato as the jointly selected ninth member.

What is Leslie Donato's professional background before joining Mallinckrodt's board?

Donato was EVP and Chief Strategy Officer at Cencora, spent 10 years at Bayer Healthcare Pharmaceuticals in leadership roles, and was a partner at McKinsey & Company for 14 years leading their Pharmaceutical & Medical Products Marketing & Sales Practice.

When did Mallinckrodt complete its merger with Endo?

Mallinckrodt completed its merger with Endo on August 1, 2025, creating a global, scaled, diversified therapeutics leader.

What were Leslie Donato's achievements at Cencora?

At Cencora, Donato executed M&A and growth strategies deploying over $10 billion in capital, contributing to a 130% increase in the company's market capitalization over five years.